We further analyzed the number and proportion of infection-related adverse event reports under different complement inhibitor categories (C3 inhibitors, C5 inhibitors, and Factor B inhibitors) (Figure 2B) and found that a higher number of reports were associated with C5 inhibitor treatment, which might be related to the broad indications and higher clinical usage volume of this type of inhibitor. The gene discussed is C5; the disease is infection.